Screener

Eligibility screening

Methylnaltrexone in Resectable Head and Neck Squamous Cell Carcinoma (MINK). A Window of Opportunity Pilot Study

Sponsored by M.D. Anderson Cancer CenterStudy detailsClinicalTrials.gov

1 US site in TX

Before we begin

Who are you filling this out for?

Your answer affects how the questions are phrased.